Strata Critical Medical insider reports RSU tax share withholding

Strata Critical Medical, Inc. reported an insider equity transaction by director and Co‑CEO and CFO William A. Heyburn on 12/10/2025.

Rhea-AI Filing Summary

Strata Critical Medical, Inc. reported an insider equity transaction by director and Co‑CEO and CFO William A. Heyburn on 12/10/2025. The filing shows 35,348 shares of Class A common stock were withheld by the company at $4.38 per share to cover tax obligations tied to vesting restricted stock units. After this tax withholding, he directly beneficially owned 1,368,088 shares of Class A common stock.

Insider Trade Summary

Exercise Price or Tax Liability: 35,348 shares

Exercise Price or Tax Liability 1 txn

Insider Heyburn William A.

Role Co-CEO and CFO

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Class A common stock, $0.0001 par value per share	35,348	$4.38	$155K

Holdings After Transaction: Class A common stock, $0.0001 par value per share — 1,368,088 shares (Direct)

Footnotes (1)

1. F1. Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Strata Critical Medical, Inc. (SRTA) report?

The company reported that 35,348 shares of Class A common stock were withheld from director and Co‑CEO and CFO William A. Heyburn to satisfy tax withholding obligations related to vesting restricted stock units.

Who is the insider in this Strata Critical Medical (SRTA) filing and what is their role?

The insider is William A. Heyburn, who is identified as a director and officer, serving as Co‑CEO and CFO of Strata Critical Medical, Inc.

On what date did the Strata Critical Medical RSU-related tax withholding occur?

The tax-related share withholding transaction occurred on 12/10/2025, as reported in the filing.

At what price were Strata Critical Medical shares withheld for taxes in this transaction?

The 35,348 withheld shares of Class A common stock were valued at a price of $4.38 per share for the tax withholding transaction.

How many Strata Critical Medical shares does the insider own after the reported transaction?

Following the reported tax withholding, William A. Heyburn beneficially owned 1,368,088 shares of Strata Critical Medical Class A common stock, held directly.

Why were the Strata Critical Medical shares withheld from the insider?

According to the explanation, the shares were withheld by the issuer to satisfy tax withholding obligations arising from the vesting of restricted stock units.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 12/12/2025 - 04:06 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Heyburn William A.

(Last) (First) (Middle)

C/O STRATA CRITICAL MEDICAL, INC.

31 HUDSON YARDS, 14TH FLOOR

(Street)

NEW YORK NY 10001

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Strata Critical Medical, Inc. [ SRTA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Co-CEO and CFO

3. Date of Earliest Transaction (Month/Day/Year)
12/10/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A common stock, $0.0001 par value per share	12/10/2025		F(1)		35,348	D	$4.38	1,368,088	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units.

Remarks:

	/s/ Melissa M. Tomkiel, as attorney-in-fact for William A. Heyburn	12/10/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.